Wall Street analysts expect that Stealth BioTherapeutics Corp (NASDAQ:MITO) will report earnings per share of ($0.02) for the current quarter, Zacks reports. Zero analysts have provided estimates for Stealth BioTherapeutics’ earnings. Stealth BioTherapeutics also posted earnings of ($0.02) per share in the same quarter last year. The business is expected to issue its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.07) per share for the current year, with EPS estimates ranging from ($0.07) to ($0.06). For the next year, analysts forecast that the business will report earnings of ($0.07) per share, with EPS estimates ranging from ($0.07) to ($0.06). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last issued its quarterly earnings results on Thursday, August 5th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01).
A number of institutional investors have recently added to or reduced their stakes in MITO. Ikarian Capital LLC raised its position in shares of Stealth BioTherapeutics by 1,995.9% in the 1st quarter. Ikarian Capital LLC now owns 788,014 shares of the company’s stock valued at $1,237,000 after purchasing an additional 750,417 shares in the last quarter. Renaissance Technologies LLC grew its stake in Stealth BioTherapeutics by 55.1% during the 1st quarter. Renaissance Technologies LLC now owns 881,346 shares of the company’s stock worth $1,384,000 after buying an additional 313,182 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in Stealth BioTherapeutics during the 2nd quarter worth $138,000. Citadel Advisors LLC grew its stake in Stealth BioTherapeutics by 234.3% during the 1st quarter. Citadel Advisors LLC now owns 112,439 shares of the company’s stock worth $177,000 after buying an additional 78,804 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Stealth BioTherapeutics in the first quarter worth $100,000. 1.70% of the stock is currently owned by hedge funds and other institutional investors.
Stealth BioTherapeutics stock traded down $0.06 during mid-day trading on Friday, hitting $1.42. The company had a trading volume of 704 shares, compared to its average volume of 435,558. The stock has a market cap of $81.76 million, a price-to-earnings ratio of -3.52 and a beta of 1.89. The business has a fifty day moving average of $1.33 and a 200 day moving average of $1.38. Stealth BioTherapeutics has a 1 year low of $1.06 and a 1 year high of $2.58.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in George Town, Cayman Islands.
Further Reading: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.